BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23836159)

  • 1. [Drug treatment of metastatic renal cell carcinoma].
    Rafiyan MR; Jäger E
    Dtsch Med Wochenschr; 2013 Aug; 138(31-32):1567-70. PubMed ID: 23836159
    [No Abstract]   [Full Text] [Related]  

  • 2. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
    Carver BS
    J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
    [No Abstract]   [Full Text] [Related]  

  • 3. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
    Sengeløv L; Geertsen PF;
    Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiogenetic pathway as a therapeutic target in renal cell carcinoma.
    Bianconi M; Scartozzi M; Faloppi L; Bittoni A; Maccaroni E; Giampieri R; Del Prete M; Burattini L; Cascinu S
    Anal Quant Cytol Histol; 2012 Feb; 34(1):15-22. PubMed ID: 22590815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
    Roviello G; Generali D
    Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
    De Pasquale MD; Pessolano R; Boldrini R; Ilari I; Donfrancesco A; Cortesi E; Jenkner A
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):e176-9. PubMed ID: 21552143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
    Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
    Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
    [No Abstract]   [Full Text] [Related]  

  • 8. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 9. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
    Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
    [No Abstract]   [Full Text] [Related]  

  • 10. [Metastatic renal cell carcinoma: pretherapeutic approach before antiangiogenic treatment. A case report].
    Méjean A; Guy L; Jacqmin D; Joly F; Négrier S; Pignot G
    Prog Urol; 2010 Mar; 20 Suppl 1():S16-9. PubMed ID: 20493437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 12. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M; Douis H; Porfiri E
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
    Hainsworth JD; Sosman JA; Spigel DR; Edwards DL; Baughman C; Greco A
    J Clin Oncol; 2005 Nov; 23(31):7889-96. PubMed ID: 16204015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
    Bukowski RM
    Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
    [No Abstract]   [Full Text] [Related]  

  • 15. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nexavar clinical registry].
    Büchler T
    Klin Onkol; 2010; 23(4):269-70. PubMed ID: 20806826
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current state of systemic therapy of metastatic renal cell carcinoma].
    Merseburger AS; Waalkes S; Kuczyk MA
    Urologe A; 2009 Sep; 48(9):983-4, 986, 988-9. PubMed ID: 19669118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
    Ficarra V; Novara G
    Eur Urol; 2008 Aug; 54(2):324-5. PubMed ID: 18485580
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
    Van Poppel H
    Eur Urol; 2008 Aug; 54(2):324. PubMed ID: 18485572
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of sorafenib in renal cell carcinoma: focus on elderly patients.
    Procopio G
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1689-92. PubMed ID: 22050017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.